Pharmaceuticals

Cybin

Cybin released FY2026 Q3 earnings on February 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.0034 (forecast USD -0.5911)

Cybin released FY2026 9 Months earnings on February 13 (EST), actual revenue USD 0, actual EPS USD -3.4965

Cybin released FY2025 Q3 earnings on February 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3799 (forecast USD -1.2003)

Cybin released FY2025 9 Months Earnings on February 11, 2025 (EST) with actual revenue of USD 0 and EPS of USD -3.0216

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Akanda

Netcapital

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Agape ATP

Co-Diagnostics

NewGenIvf

Tradr 2X Long QBTS Daily ETF

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

HELP

Helus Pharma's Interim CEO, Eric So, will present at the 29th Milken Global Conference on May 4, focusing on mental health innovation. The session will be available on the company's investor relations site, highlighting Helus Pharma's contributions to emerging mental health therapies. The latest analyst rating for Helus Pharma (HELP) stock is a Buy, with a price target of $95. The company is developing novel serotonergic agonists to address major mental health issues, including depression and anxiety, with ongoing clinical trials for its candidates.

Tip Ranks

Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference

SBIO

LABU

H.C. Wainwright analyst Patrick Trucchio has maintained a Buy rating on Helus Pharma (HELP) with a price target of $95.00. Trucchio, a 5-star analyst with a 27.2% average return, reports that the consensus on Helus Pharma is a Strong Buy, with an average price target of $41.17. He also covers other healthcare stocks like Atai Beckley N.V. and Immunocore Holdings.

ALPS Medical Breakthrough

iShares US Pharma

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VG Health

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares Global Healthcare

VanEck Biotech ETF

AtaiBeckley

Definium Therapeutics

Immunocore

H.C. Wainwright Keeps Their Buy Rating on Helus Pharma (HELP)

Helus Pharma™ (NASDAQ: HELP) announced a collaboration with TARA Mind to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting Major Depressive Disorder, particularly within the veteran community. This partnership aligns with President Trump's Executive Order aimed at enhancing clinical research participation for veterans facing mental health challenges. Helus Pharma's shares rose by 2.5 cents to $5.42 as they emphasize the importance of expanding access to innovative treatments for serious mental illness.

Baystreet

Helus Ekes up on Hookup with TARA Mind

SEEL

SEELQ

CYBN

ATAI

DFTX

CMPS

PSIL

President Trump has signed an executive order to ease research restrictions on psychedelic medicine, inspired by a text from podcaster Joe Rogan. This move aims to legitimize an industry hindered by federal regulations since the 1970s. The order directs federal agencies to facilitate access to experimental treatments for terminally ill patients and allocates $50 million for state-level research into ibogaine. Advocates express cautious optimism about potential mental health benefits, although widespread access remains uncertain without further action. The FDA will also expedite approval processes for promising psychedelic therapies.

Thehill

Seelos Therapeutics

SEELOS THERAPEUTICS INC

iBio

Compass Pathways

Impact BioMedical

Invesco Nasdaq Biotechnology ETF

AdvisorShares Psychedelics ETF

Trump’s Rogan-inspired psychedelics order stokes cautious optimism

Helus Pharma supports a new U.S. Executive Order aimed at accelerating research and access to psychedelic treatments for serious mental health conditions. The order includes measures for priority FDA reviews and expanded patient access. Helus's lead program, HLP003, is in Phase 3 for treating major depressive disorder and is positioned to benefit from this supportive policy. The company emphasizes the need for innovative treatment options as many patients inadequately respond to current therapies. Analysts rate Helus Pharma stock (HELP) as a Buy with a $95 price target.

Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways

SILO

GHRS

IXHL

DRUG

Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use

businessinsider

Silo Pharma

GH Research

Incannex Healthcare

Bright Minds Biosciences

Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use

Cybin(HELP.US)

Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference

H.C. Wainwright Keeps Their Buy Rating on Helus Pharma (HELP)

Helus Ekes up on Hookup with TARA Mind

Trump’s Rogan-inspired psychedelics order stokes cautious optimism

Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways

Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use